Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 09:57:16 2024-04-23 am EDT			5-day change	1st Jan Change
27.28 ^EUR	-0.12%		+4.12%	-19.25%

03:02pm	Bayer: licensing agreement for biological insecticide	CF
11:33am	BAYER AG : Deutsche Bank reiterates its Neutral rating	ZD

BAYER AG : JP Morgan remains Neutral

February 25, 2021 at 07:31 am EST

Initially Neutral on the company, JP Morgan's analyst Richard Vosser maintained his recommendation. The target price is unchanged at EUR 53.

Latest news about Bayer AG

Bayer: licensing agreement for biological insecticide	09:02am	CF
BAYER AG : Deutsche Bank reiterates its Neutral rating	05:33am	ZD
Bayer, AlphaBio Control Sign Exclusive License Deal for Biological Insecticide	04:11am	MT
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	Apr. 22	MT
JPMorgan rates Bayer at 'Neutral' - Target 34 euros	Apr. 22	DP
BAYER AG : JP Morgan remains Neutral	Apr. 22	ZD
Bayer Signs Renewable Energy Purchase Deal for Six German Sites	Apr. 19	MT
Bayer: signs renewable energy supply contract	Apr. 19	CF
Capgemini: new platform implemented for Bayer	Apr. 19	CF
TV ratings: Bayer's Europa League success brings RTL many viewers	Apr. 19	DP
Bayer’s Investigational Gene Therapy for Heart Failure Gets US FDA Fast Track Designation	Apr. 18	MT
AskBio receives FDA Fast Track Designation for AB-1002 Investigational Gene Therapy Program in Congestive Heart Failure	Apr. 18	CI
Bayer: fast-track procedure in cardiology in the USA	Apr. 18	CF
Study: US companies outpace Europe and Asia in research spending	Apr. 18	DP
Stifel Cuts Bayer PT, Keeps Hold Rating	Apr. 17	MT
Sat.1 to show top match between FC Bayern and Stuttgart	Apr. 17	DP
Conti slumps to early November level after figures	Apr. 17	DP
BAYER : Stifel lowers its target price	Apr. 17	CF
Bayer: presents results on Parkinson's disease	Apr. 16	CF
Bayer AG and Asklepios BioPharmaceutical, Inc Presents Results from the 18-Month Phase Ib Clinical Trial for AB-1005	Apr. 16	CI
Boehringer replaces Bayer as Germany's largest drugmaker on Jardiance gains	Apr. 16	RE
Eurozone Industrial Production Recovery Boosts German Stocks Amid Growing Tensions in Middle East	Apr. 15	MT
UBS Trims Bayer PT, Maintains Neutral Rating	Apr. 15	MT
BAYER AG : Barclays reaffirms its Neutral rating	Apr. 15	ZD
Nutrien Plans Exit From Argentina, Chile	Apr. 15	MT

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.5%). Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).

Sector

Pharmaceuticals

Calendar

2024-04-26 - Annual General Meeting

Related indices

EURO STOXX 50 , STOXX EUROPE 600 (EUR) , DAX

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

BAYER : Another peer group tidy up

April 14, 2024 at 03:26 pm EDT

Bayer AG: Not out of the woods yet

March 06, 2024 at 10:46 am EST

More Strategies

Ratings for Bayer AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

27.32 EUR

Average target price

37.05 EUR

Spread / Average Target

+35.63%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BAYER AG	-19.27%	28.56B
ELI LILLY AND COMPANY	+25.92%	659B
NOVO NORDISK A/S	+26.74%	557B
JOHNSON & JOHNSON	-4.90%	359B
MERCK & CO., INC.	+17.15%	322B
ABBVIE INC.	+9.31%	297B
ASTRAZENECA PLC	+6.31%	215B
NOVARTIS AG	+5.31%	210B
ROCHE HOLDING AG	-5.93%	200B
PFIZER, INC.	-8.46%	149B

Other Pharmaceuticals

Bayer AG

Equities

BAYN

DE000BAY0017

Pharmaceuticals

BAYER AG : JP Morgan remains Neutral

Latest news about Bayer AG

Chart Bayer AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Bayer AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals